S&P 5007,666.60▲0.5% Nasdaq26,217.83▲0.5% Dow53,061.95▲0.6% Russell 2K2,953.17▲1.1% 10-Yr4.80%+0bp VIX15.20−1.14 WTI$90.70▲0.5% Gold$4,431.70▲1.9% EUR/USD1.159▼0.1% BTC$78,715▼0.5% Nikkei66,215▼0.1%
At close · Thu, Sep 3, 2026
Daily Market Updates.

Global Markets

Home›Global Markets›Europe›Novartis shares drop after del-desiran trial disappoin…

Novartis shares drop after del-desiran trial disappoints investors

The slide follows disappointing results from the companys del-desiran drug trial, after which investors reduced the stock by 9.0% on the day.

Reported · Written up by our desk · Europe

Novartis shares fell about 9.0% on Tuesday after the latest results from a del-desiran drug trial disappointed investors, according to CNBC Markets.

CNBC World reported the same drop, tying the decline to setbacks seen in the trial outcome for the del-desiran therapy.

The move underscores how late-stage trial results can quickly change sentiment around pharmaceutical pipeline assets, with trading reacting immediately to the disappointing data.

← Newer storyBrent rises above $99 after confirmed Houthi attack on Saudi Arabia

More like this

Global MarketsMistral raises $3.5 billion in a bid to expand its AI push
Global MarketsAlbania pitches affordable dental implants as medical tourism hub
Global MarketsJapan’s military buildup prompts scrutiny of defense spending plans
Global MarketsHK to pursue contractor compensation over delayed hospital lift work
Global MarketsMistral wins funding that values the AI startup at $24 billion

Sources

CNBC MarketsPharma major Novartis falls 9% after three drug trial setbacks
CNBC WorldPharma major Novartis falls 9% after three drug trial setbacks

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.